Redeye: Xvivo Perfusion - And the beat goes on
Redeye argues that the negative YTD share price performance does not reflect Xvivo’s underlying fundamental developments. We see a doubling potential in the share for this emerging niche leader in the coming 12 months, driven by strengthening sentiment and several near-term catalysts.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/